Noboru Yamamoto

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Ramelteon for prevention of postoperative delirium in elderly cancer patients: A randomized, double-blind, placebo-controlled multicenter trial, JORTC-PON02/J-SUPPORT2103/NCCH2103.

  Journal of Clinical Oncology · 2026-06-03

• ENVELOPE trial (NCCH2412): Enfortumab vedotin in patients with locally advanced or metastatic small bowel adenocarcinoma refractory or intolerant to platinum-based combination therapy—A multicenter, phase II trial (trial in progress).

  Journal of Clinical Oncology · 2026-05-28

• Class-specific clinical and molecular features of <i>SMARCA4</i> alterations in non–small cell lung cancer.

  Journal of Clinical Oncology · 2026-05-28

• The SOS1 Inhibitor BI 1701963 as Monotherapy or in Combination with Trametinib in Patients with <i>KRAS</i> Mutation-Positive Solid Tumors

  Clinical Cancer Research · 2026-04-28

• Additional file 1 of Tolerability and safety of magrolimab (ONO-7913) in Japanese patients with advanced or metastatic solid tumors: a phase 1, open-label, uncontrolled, dose-escalation study

  Figshare · 2026-03-26

• Additional file 1 of Tolerability and safety of magrolimab (ONO-7913) in Japanese patients with advanced or metastatic solid tumors: a phase 1, open-label, uncontrolled, dose-escalation study

  Figshare · 2026-03-26

• Tolerability and safety of magrolimab (ONO-7913) in Japanese patients with advanced or metastatic solid tumors: a phase 1, open-label, uncontrolled, dose-escalation study

  Figshare · 2026-03-26

• Tolerability and safety of magrolimab (ONO-7913) in Japanese patients with advanced or metastatic solid tumors: a phase 1, open-label, uncontrolled, dose-escalation study

  Figshare · 2026-03-26

• Early Mycophenolate Mofetil Combination Therapy as an Effective Approach for Immune‐Related Hepatitis Induced by Immune Checkpoint Inhibitors in Patients With Solid Tumor

  Cancer Medicine · 2026-03-01

• Study protocol for a phase I investigator-initiated clinical trial of E7820 in Japanese patients with unresectable solid tumours: CIRCUS trial (NCCH2303)

  Japanese Journal of Clinical Oncology · 2026-02-19

• Implementing generative artificial intelligence in precision oncology: safety, governance, and significance

  Journal of Hematology & Oncology · 2026-02-09 · 1 citations

• Clinical Activity of MET-TKIs in METex14 Skipping NSCLC With Poor Performance Status

  Anticancer Research · 2026-01-30

• Supplementary Methods from The MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study

  2025-12-11

• Supplementary Table 2 from The MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study

  2025-12-11

• Supplementary Figure S2 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with &lt;i&gt;MDM2&lt;/i&gt; Amplification: An Open-Label Phase Ib/II Study

  2025-12-11

• Supplementary Figure S3 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with &lt;i&gt;MDM2&lt;/i&gt; Amplification: An Open-Label Phase Ib/II Study

  2025-12-11

• Supplementary Figure S4B from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with &lt;i&gt;MDM2&lt;/i&gt; Amplification: An Open-Label Phase Ib/II Study

  2025-12-11

• Supplementary Figure S4A from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with &lt;i&gt;MDM2&lt;/i&gt; Amplification: An Open-Label Phase Ib/II Study

  2025-12-11

• Supplementary Figure S1 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with &lt;i&gt;MDM2&lt;/i&gt; Amplification: An Open-Label Phase Ib/II Study

  2025-12-11

• Supplementary Table S1 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with &lt;i&gt;MDM2&lt;/i&gt; Amplification: An Open-Label Phase Ib/II Study

  2025-12-11